ARTICLE | Company News
FDA approves Dupixent for asthma
October 19, 2018 10:42 PM UTC
FDA approved Dupixent dupilumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat moderate to severe eosinophilic or corticosteroid-dependent asthma in patients ages 12 and older.
Sanofi said the drug’s wholesale acquisition cost (WAC) of $2,931.54 will remain unchanged...